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The p53 protein is activated in response to DNA damage, trig-
gering pathways leading either to cell cycle arrest or apoptosis
(reviewed by Gottlieb and Oren, 1996; Ko and Prives, 1996;
Levine, 1997). The central core domain of p53 (amino acids
102–292) can bind with sequence-specificity to DNA elements
(Cho et al, 1994). In this way p53 can transactivate the expression
of ta rget genes which includ e  p21, a cyclin-dependent kinase
inhibitor (El-Diery et al, 1993), and Bax, a promoter of apoptosis
(Miyashita and Reed, 1995). Additional evidence suggests that
p53 can act as a tumour suppressor independently of its transacti-
vation function (Caelles et al, 1994; Haupt et al, 1995; Haupt et al,
1996), though the mechanisms of this activity are not understood.
In human cance r, mutant forms of p53 commonly lose the capacity
for sequence-specific DNA binding which is required for the
transactivation of ta rget genes (Cho et al, 1994). These mutations
a ffect the core domain and can be classified into two main groups:
(i) DNA contact mutants which have an altered residue normally
involved in making direct contact with the DNA ta rget sequence,
and (ii) structural mutants which have altered conformation of the
central core domain (Cho et al, 1994). Conformational folding is
crucial for the correct positioning of the DNA contact residues and
structural perturbation of the core is predicted to disrupt the
specific interaction with DNA ta rget sequences, resulting in loss of
transactivation function.
p53 can also bind sites of DNA damage, such as mismatches and
double-strand DNA ends (Lee et al, 1995), as well as short single-
stranded DNAs (Jayaraman and Prives, 1995). This binding
involves the carboxy terminus of the p53 protein and interaction
with mismatched DN A  in vit roresults in p53 unde rgoing a specific,
limited proteolytic cleavage reaction (Molinari et al, 1996;
Okorokov et al, 1997). The DNA bound fraction of the cleavage
reaction contains full-length p53 and a 4 0 kDa fragment lacking the
amino terminal domain of the protein. The supernatant fraction
contains a 3 5 kDa fragment, which is released from the
DNA/protein complex. This fragment lacks both the amino and
carboxy terminal domains, and retains a conformationally wild-type
central core domain. It has been proposed that the proteolytic
cleavage may be autocatalytic and play a role in the activation of
p53 in response to DNA damage in vivo since p53 fragments of
similar size have been observed following treatment of cells with
DNA damaging agents (Molinari et al, 1996; Okorokov et al, 1997).
In the present stud y, we have asked whether mutant p53 under-
goes the same cleavage reaction as the wild-type protein when
incubated with DNA in vitro. For this purpose we generated a
series of murine p53 mutants by site directed mutagenesis. Each
mutant was expressed in vitro using rabbit reticulocyte lysate for
translation (according to Milner et al, 1991) and assayed for the
capacity to bind mismatched DNA and unde rgo proteolytic
cleavage. The reason that murine, rather than human, p53 was
chosen for this study is that the human protein produces a number
of internal initiation products when translated in vitro, with a
major product at 4 0 kDa. This complicates analysis of the proteo-
lytic cleavage products induced in response to mismatched DNA.
With murine p53 this problem is not encountered.
MATERIALS AND METHODS
Site-directed mutagenesis and subcloning
Mutagenesis was carried out using the vector pSELEC T-1
(Promega) with the murin e p53gene cloned downstream of the T7
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promoter. Single-stranded DNA copies of the construct were
harvested following R408 helper phage infection of transformed
XL1-blue-MRF’ Kanr cells. Two primers were annealed to the
ssDNA, one to repair a mutated gene for ampicillin resistance and
the primer coding for the required mutation in the murine p53
gene. Annealed primer/templates were incubated for 3 h at 37°C
with T4 DNA polymerase (7.5 units) and T4 DNA ligase (3 units)
in a typical 30 ml reaction, transformed into XL1 blue-MRF’ cells
and selection carried out with Ampicillin at 125 mgm l –1.
Mutations in the p53 gene of Ampr clones were confirmed initially
by restriction digestion (where a new restriction site had been
incorporated into the mutagenesis oligonucleotide) and by subse-
quent DNA sequencing.
Mutant  p53 genes were sub-cloned into pGEM11ZF– down-
stream of an SP6 promoter for expression in vitro. After restriction
digestion, vector and insert bands were excised from a 0.8%
agarose gel and isolated using a Geneclean kit (Bio101) or spin
column kit (IGI) before ligation. DNA templates for in vitro tran-
scription were prepared using the QIAGEN ‘midiprep’ protocol.
In vitro transcription, translation and
immunoprecipitation
In vitro transcription, translation and immunoprecipitation were as
described previously (Milner et al, 1991) using plasmids encoding
the wild-type or mutant p53 gene under an SP6 promoter.
Oligonucleotides for DNA binding
The following oligonucleotides were employed: p53 consensus
(CON-DNA; 20 bp), 5¢biotin GGACATGCCCGGGCATGTCC-3¢
(Funk et al, 1992), lesion DNA (L-DNA; 60 bp) 5¢ GCTCGAACC-
CGTTCTCGGAGCACCCCTGCCCCAGCCCAACCGCTTTG-
GCCGCCGCCCAGC-3¢ (Lee et al, 1995) triple cytosine loops
underlined. The oligonucleotides were annealed as follows: CON-
DNA to itself, L-DNA to the biotinylated reverse sequence 5¢biotin
GCTGGGCGGCGGCCAAAGCGGTTCTGCAGTGCTCCGA-
GAACGGGTTCGAGC-3¢.
DNA binding/proteolytic cleavage assays
Streptavidin-coated magnetic Dynabeads (Dynal) were used to
harvest biotinylated DNA–protein complexes. Annealed CON-
DNA or L-DNA oligonucleotides were bound to the beads
(30 pmol of oligonucleotide + 15-ml beads) in TE pH 7.5; 1 M
sodium chloride (NaCl) for 20 min at 20°C, washed with 2 ´ 400
ml TE–NaC1, and 2 ´ 400 ml DNA-binding buffer (20 mM
Tris–HC1, pH 7.5; 100 mM NaCl; 0.1% NP40; 10% glycerol;
5m M dithiothreitol). The beads suspended in DNA binding buffer
were then incubated with [35S]-methionine labelled p53 for 20 min
at 20°C. The beads with DNA–p53 complexes were washed with
3 ´ 400 ml DNA-binding buffer and resuspended in 50 ml. Samples
were incubated for 1 h at 37°C. The supernatant was removed and
Table 1 DNA contact and structural mutants of murine p53
Class of mutant Murine mutant Human equivalent Mutagenesis oligonucleotide
DNA contact R270H R273H 5¢-ggacagctttgaggtgcacgtttgtgcctgccc-3¢
R245H R248H 5¢-cctgcatgggaggcatgaaccaccggccgatccttaccatcatcacactgg-3¢
K117A K120A 5¢-cttcctgcagtctgggaccgcggcgtctgttatgtgcacgtac-3¢
Structural R172H R175H 5¢-gacggaggtcgtgagacactgcccccaccatgag-3¢
A135V A138V *
C173F C176F *
C173M C176M *
C173D C176D *
*Already available.
Table 2 Phosphorylation mutants of murine p53
Mutant Kinase Mutagenesis oligonucleotide
N-terminus S18A DNAPK 5¢-gcctcgagctccctcttgcgcaggagacattttcaggc-3¢
S18D 5¢-gcctcgagctccctcttgatcaggagacatttcaggc-3¢
S37D JNK 5¢-ctccagaagatatcctgccagatcctcactgcatggacgatc-3¢
C-terminus S312A CDK 5¢-ctgcccacctgcacaagcgcagctcccccgcaaaagaaaaaacc-3¢
S312D 5¢-ctgcccacctgcacaagcgcagatcccccgcaaaagaaaaaacc-3¢
S373A PKC 5¢-gaagaccaagaagggccaggcgacgtcccgccataaaaaaacaatgg-3¢
S373D 5¢-ctgaagaccaagaagggccaggatactagtcgccataaaaaaacaatggtc-3¢
S375A 5¢-ccaagaagggccagtctaccgcgcgccataaaaaaacaatggtc-3¢
S375D 5¢-ccaagaagggccagtccgatcgccataaaaaaacaatggtc-3¢
S373D+S37 5¢-ctgaagaccaggaggggccaggatactgaccgcgataaaaaaacaatggtc-3¢
S389A CKII *
S389D *
*Already available.214 T Mee et al
British Journal of Cancer (1999) 81(2), 212–218 © 1999 Cancer Research Campaign
mixed with 30 ml Laemmli’s buffer. The beads were washed with
3 ´ 400 ml DNA-binding buffer and resuspended in 30 ml
Laemmli’s buffer. Reaction products were analysed by sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
(15%) and autoradiography.
Cell culture and immunoblotting
Clone 6 cells (rat embryo fibroblasts expressing the murine
temperature sensitive mutant p53 A135V) (Michalovitz et al,
1990) were maintained in culture at 37°C in Iscove’s medium
supplemented with 10% fetal calf serum. For experimentation, the
cells were sub-cultured and parallel cultures were incubated at
either 32°C (p53 wild-type phenotype) or 37°C (p53 mutant
phenotype) for 24 h prior to addition of cis-platinum (0, 1, 10 or
20 mg ml–1). After a further 18 h the cells were trypsinized, washed
twice with ice-cold phosphate-buffered saline, and counted prior to
addition of Laemmli’s buffer to give 104 cells  m1–1. Total cell
lysates were analysed by SDS-PAGE and immunoblotting (as
detailed in Okorokov et al, 1997) using anti-p53 monoclonal anti-
bodies PAb248 (N-terminus), PAb240 (core domain) and PAb421
(C-terminus).
RESULTS AND DISCUSSION
We were particularly interested to ask if naturally occurring mutants
of p53 retain the ability to undergo proteolytic cleavage, and this
series of mutants included: (i) DNA contact mutants, and (ii) struc-
tural mutants of murine p53 (Table 1). In particular this allowed us
to ascertain whether murine p53 mutants, analogous to hotspot
mutants commonly found in human cancer, abrogate the capacity of
p53 to bind mismatched DNA and undergo proteolytic cleavage
(the numbering of equivalent human mutants is included in Table
1). Analysis of structural mutants with abnormal conformation also
enabled us to determine the importance of the tertiary structure of
p53 for the cleavage reaction.
Each mutant was labelled with [35S]-methionine during transla-
tion in rabbit reticulocyte lysate, and characterized by immunopre-
cipitation with a panel of monoclonal antibodies (Milner et al,
1991). Binding to a sequence-specific consensus DNA target
(CON-DNA), (Funk et al, 1992) was also determined. Wild-type
p53 was included as a positive control in every experiment: it
displayed 246+ 1620+ 2400 immunoreactivity (Figure 1A) and
showed sequence-specific DNA binding (Figure 1B), as predicted
for the correctly folded, conformationally wild-type protein. No
cleavage products were released from the p53–CON-DNA
complexes (Figure 1B). Ability to undergo proteolytic cleavage
was assayed by incubation with a mismatched DNA target which
contained triple cytosine loops (L-DNA), (Lee et al, 1995;
Molinari et al, 1996). On incubation with mismatched DNA, wild-
type p53 was cleaved to yield the characteristic pattern of roughly
equivalent levels of full length and 40-kDa protein bound to the
DNA, with release of the 35-kDa cleavage product from the
p53–DNA complexes (Figure 1B). These results are consistent
with the previous observations of Molinari et al (1996) and
Okorokov et al (1997).
The group of DNA contact mutants comprised R245H, R270H
and K117A (equivalent to R248H, R273H and K120A in human
p53, see Table 1). It is important to note that substitution of DNA
contact residues on the surface of the p53 core domain is not
predicted to perturb normal conformational folding and, as
expected, the DNA contact mutants retained the wild-type
immunoprecipitation phenotype (Figure 2A). Sequence-specific
DNA binding by the DNA contact mutants was either completely
lost (R245H, R270H) or greatly reduced (K117A) (Figure 2B).
The apparent low level binding by K117A to CON-DNA may
reflect interaction with the dsDNA ends of the oligonucleotide.
Despite loss of sequence-specific DNA binding, the binding to
Table 3 Summary of results
p53 Mutant Conformation CON-DNA L-DNA Proteolytic
1620 240 binding binding Cleavage
Wild-type + 0 +++ +++ +++
DNA contact mutants R270H + 0 0 +++ +++
R245H + 0 0 +++ +++
K117A + 0 + +++ +++
Structural mutants R172H 0 + 0 ++ 0
A135V 0 + 0 ++ 0
C173F + + 0 ++ 0
C173M + + 0 ++ 0
C173D + + 0 ++ 0
Phosphorylation mutants S18A + 0 +++ +++ +++
S18D + 0 +++ +++ +++
S37D + 0 +++ +++ +++
S312A + 0 +++ +++ +++
S312D + 0 +++ +++ +++
S373A + 0 +++ +++ +++
S373D + 0 +++ +++ +++
S375A + 0 +++ +++ +++
S375D + 0 +++ +++ +++
S373D+ + 0 +++ +++ +++
S375D
S389A + 0 +++ +++ +++
S389D + 0 +++ +++ +++Proteolytic cleavage of p53 mutants 215
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mismatched DNA appeared unaffected by substitution of DNA
contact residues R245, R270 and K117 since all three mutants
bound the mismatched DNA target (Figure 2B). Moreover,
binding to mismatched DNA was accompanied by proteolytic
cleavage to generate the 40-kDa and 35-kDa cleavage products of
the mutant protein (Figure 2B). Indeed, the ability of DNA contact
mutants to bind the mismatched DNA target and undergo proteo-
lytic cleavage was very similar to that of the wild-type protein
(compare Figure 1B and Figure 2B).
Proteolytic cleavage of p53 may represent an autocatalytic
process (Molinari et al, 1996; Okorokov et al, 1997). In which case
it would be predicted to involve residues exposed on the native
p53 protein. A number of naturally occurring serine catalytic
dyads are known to exist on other proteins (reviewed in Paetzel
and Dalbey, 1997), and computer-based analysis of the central
core domain of p53 suggested that K117 may represent part of a
catalytic dyad by association with S118 or C274. The positioning
of these residues on the surface of p53 is indicated in Figure 3. In
the light of this information we reasoned that K117 may play a
catalytic role in the proteolytic cleavage of p53. However, we now
show that substitution of K117 to alanine (which would be unable
to associate with S118 or C274 in dyad formation) does not affect
cleavage, indicating that K117 is dispensable for the proteolytic
cleavage reaction of p53 and is therefore unlikely to participate in
the catalytic process.
The second group of p53 mutants were structural (listed in Table
1). All showed loss of wild-type conformational structure, as indi-
cated by exposure of the 240 epitope (normally cryptic for wild-
type p53), (Gannon et al, 1990), loss of 1620 reactivity and loss of
sequence-specific DNA binding (see Figure 4A for examples;
summarized in Table 3). Despite loss of structural integrity and
sequence-specific DNA binding ability (Figure 4B), these mutants
retained the capacity to bind mismatched DNA (Figure 4B) indi-
cating that altered conformational structure does not impede
binding to a mismatched DNA target. However, there was no
Total
421
248
246
1620
240
419
p53
Total B S B S
CON-DNA L-DNA
1234567
p53
40 kDa
35 kDa
B
A
Total
421
248
246
1620
240
419
Total BS BS
CON-DNA L-DNA
1234567
B
A
p53
p53
p53
R270H
R245H
K117A
p53
40 kDa
35 kDa
p53
40 kDa
35 kDa
p53
40 kDa
35 kDa
R270H
R245H
K117A
Figure 1 (A) Immunoprecipitation of wild-type, in vitro translated murine
p53 with a panel of monoclonal antibodies, as detailed by Milner et al (1991).
The [35S]-labelled protein displays a typical wild-type conformational
phenotype, indicated by immunoreactivity with PAb246 and PAb1620, and
lack of reactivity with PAb240. PAb421 and PAb248 detect carboxy and
amino terminal epitopes respectively, and PAb419 is a negative control
antibody. Proteins were resolved by 15% SDS–PAGE and visualized by
autoradiography. (B) DNA binding and proteolytic cleavage of wild-type p53
(as detailed by Molinari et al (1996)). Briefly, biotinylated DNA was bound to
streptavidin coated magnetic beads (Dynal) and the beads were washed to
remove unbound oligonucleotides. In vitro translated [35S]-labelled p53 was
incubated with the DNA-coated beads and the beads were then washed to
remove any unbound protein. The beads, with bound p53–DNA complexes,
were resuspended in DNA-binding buffer (Molinari et al, 1996) and incubated
at 37°C for 1 h. The incubated complexes were separated into beads (B) and
supernatant (S) fractions, representing DNA bound and released fractions of
the protein respectively. Equivalent aliquots of each sample were resolved by
SDS-PAGE and visualized by autoradiography. An aliquot of the ‘total’
translation mix was used as a marker (lane 1). Assays were carried out with
a sequence-specific target, CON-DNA (lanes 3 and 4) and with a
mismatched DNA target, lesion DNA (L-DNA; lanes 6 and 7) as indicated
Figure 2 (A) Immunoprecipitation profile and (B) DNA binding/proteolytic
cleavage of murine p53 DNA contact mutants (see Figure 1 legend for
details). The Altered Sites™ In Vitro Mutagenesis System (Promega) was
used to generate mutations in the wild-type murine p53 gene216 T Mee et al
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evidence of proteolytic cleavage and no release of the 35-kDa
product from the p53–DNA complexes (Figure 4B). We therefore
conclude that wild-type tertiary structure is crucial for the genera-
tion and release of the 35-kDa cleavage product.
Further experiments using clone 6 rat embryo fibroblasts also
indicate that cleavage products of p53 are generated in vivo
following DNA damage and that the effect is conformation depen-
dent. Clone 6 cells stably express a temperature-sensitive mutant
of murine p53, A135V, and our in vitro results clearly demonstrate
that p53 A135V binds damaged DNA but fails to undergo
cleavage to generate either the 40-kDa or 35-kDa cleavage prod-
ucts (Figure 4B). Use of clone 6 cells allowed us to test the effect
of p53 A135V conformation on the cleavage response to DNA
damage in vivo since, at 37°C, the protein adopts the mutant
phenotype, whilst at 32°C p53 A135V adopts the wild-type pheno-
type and results in cell growth arrest and apoptosis (Michalovitz et
al, 1990; and results not shown). Evidence of p53 cleavage in
response to cisplatin-induced DNA damage was observed in those
cells cultured at 32°C (Figure 5). Exposure to cisplatin was for
18 h and the observed 40-kDa cleavage product of p53 was reac-
tive with PAb240 and PAb421 but non-reactive with PAb248, indi-
cating N-terminal cleavage of p53. This is consistent with previous
results demonstrating a 40-kDa cleavage product of wild-type p53
in MCF7 cells following 18-h treatment with cisplatin (Molinari et
al, 1996). The 35-kDa cleavage product is not expected in these
samples since it appears only transiently, within 1 h exposure to
cisplatin (Molinari et al, 1996). The full-length p53 band observed
at 32°C (Figure 5) is predicted to represent both wild-type and
mutant phenotypes of p53 A135V since complete conversion to
the wild-type phenotype takes several days at 32°C (Michalovitz et
al, 1990). In contrast to the cells cultured at 32°C there was no
evidence of the 40 kDA product at 37°C (Figure 5), indicating that
p53 A135V expressed in clone 6 cells only undergoes cleavage
when it adopts the wild-type conformation. Thus the conformation
of p53 appears critical for its cleavage in response to DNA damage
both in vitro and in vivo.
The mechanisms for regulation of p53 function in vivo are not
fully understood. One way in which p53 may be regulated is by
phosphorylation. The amino and carboxy terminal domains of p53
can be phosphorylated by a number of kinases in vitro, some of
which may regulate p53 function in vivo (reviewed by Meek, 1994;
Steegenga et al, 1996). We next asked if phosphorylation might be a
way of regulating the binding of p53 to damaged DNA and/or
proteolytic cleavage induced by DNA damage. For this purpose, we
analysed a series of 12 phosphorylation site mutants of murine p53
(listed in Table 2) and assayed for their capacity to bind mismatched
DNA, and undergo proteolytic cleavage in vitro. Serine residues
were mutated to alanine or aspartic acid, to simulate the dephos-
phorylated and phosphorylated residues respectively. The series of
mutants included a double serine to aspartic acid mutant for S373
and S375 since these two residues have been implicated in phos-
phorylation by protein kinase C (PKC) (Takenaka et al, 1995; Milne
et al, 1996). All the phosphorylation site mutants behaved like wild-
type p53 in our assay system (results summarized in Table 3). This
indicates that phosphorylation at single sites may not influence
DNA binding and proteolytic cleavage. We cannot, however, rule
out the possibility that multiple phosphorylation/dephosphorylation
may regulate the cleavage reaction.
Lys117
Cys274
Ser118
Figure 3 Region on the surface of the core of p53 that represents a
putative catalytic site for autoproteolytic cleavage. For the purposes of
orientation, the carboxy terminal a-helix of the core crystal structure is on the
right of the figure. Theoretically, K117 might associate with S118 or C274 to
form a catalytic dyad. The human p53 core crystal structure (Cho et al, 1994)
was analysed using the program Molviewer (Protein Structure Group,
Department of Chemistry, University of York). Numbering of residues
according to murine p53
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Figure 4 (A) Immunoprecipitation profile and (B) DNA binding/proteolytic
cleavage of murine p53 structural mutants (see Figure 1 legend for details;
see Figure 2 legend for details of mutagenesis)Proteolytic cleavage of p53 mutants 217
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Two major points emerge from the results of this study (summa-
rized in Table 3). First, all p53 mutants analysed were able to bind
to mismatched DNA. This suggests that in human cancer, mutant
p53 retains the capacity to bind sites of DNA damage, even though
it is deficient in activating a normal p53 response to the damage.
Secondly, for proteolytic cleavage of the protein to take place, the
central core domain must be folded into the wild-type conforma-
tion. The fact that loss of structural integrity correlates with loss of
capacity for proteolytic cleavage is consistent with the idea that
p53 cleavage is an autocatalytic process requiring the correct
orientation of residues involved in the reaction. Where mutation
gives rise to a misfolded protein, those residues that would
normally interact to facilitate catalysis would be disrupted, thus
preventing cleavage (as observed for structural mutants; Figure 4B
and Table 3). Further studies are planned to determine which
residues are involved in catalytic site formation for proteolytic
cleavage of p53.
A third point concerns DNA contact mutants of p53 which
occur with high frequency in human cancer. For example, muta-
tions affecting R248 and R273 account for approximately 18% of
p53 mutations in cancer. Such mutations cause loss of p53 tran-
scriptional activation function, even though the protein retains
normal structural conformation. We now demonstrate that DNA
contact mutants retain the capacity to undergo proteolytic cleavage
in response to mismatched DNA in vitro, with release of a 35-kDa
cleavage product which is indistinguishable from that observed
with the wild-type protein. The 35-kDa product released from
wild-type p53 encompasses an intact core domain and is activated
as an aminopeptidase (Okorokov et al, 1997). It may also be
activated for other functions, such as 3¢–5¢ exonuclease activity
(Mummenbrauer et al, 1996), and/or play a role in signal transduc-
tion cascades in the cell. In the later context it is relevant to note
that the core domain of p53 has potential for interaction with target
proteins such as 53BP2 via a novel SH3-binding motif (Thukral et
al, 1994; Gorina and Pavletich 1996). Moreover, in-vivo expres-
sion of the 35-kDa core cleavage product induces G1 arrest when
transfected into p53–/– murine embryo fibroblasts (Axe TJ et al,
manuscript submitted). Since this cleavage product is released
from full-length p53 R248H (Figure 2), these combined observa-
tions indicate the possibility of inducing growth suppression of
tumour cells expressing p53 R248H and other DNA contact
mutants.
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